Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 250 of 866 entries
View as:

Impact of Adalimumab on Patient-reported Outcomes in Ulcerative Colitis

Phase: N/A Priority: Normal
NCT ID: NCT02506179 Org: User:
Start: 08/18/15 End: 02/10/20 Due: 02/10/21

Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus

Phase: N/A Priority: Normal
NCT ID: NCT05843643 Org: User:
Start: 07/19/23 End: 10/31/27 Due: 10/31/28

Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 as Monotherapy and in Combination With IV Bevacizumab

Phase: N/A Priority: Normal
NCT ID: NCT05029882 Org: User:
Start: 10/13/21 End: 11/30/27 Due: 11/30/28

Expanded Access to Glecaprevir/ Pibrentasvir

Phase: N/A Priority: Normal
NCT ID: NCT03123965 Org: User:
Start: - End: - Due: -

A Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Participants With Recurrent Ovarian Cancer With High Folate Receptor-Alpha Expression

Phase: N/A Priority: Normal
NCT ID: NCT06365853 Org: User:
Start: 07/29/24 End: 06/30/27 Due: 06/30/28

Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unresectable Metastatic Colorectal Cancer in Combination With IV Fluorouracil, Folinic Acid, and Bevacizumab

Phase: N/A Priority: Normal
NCT ID: NCT06107413 Org: User:
Start: 11/12/23 End: 10/31/26 Due: 10/31/27

A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo

Phase: N/A Priority: Normal
NCT ID: NCT06118411 Org: User:
Start: 12/19/23 End: 02/29/28 Due: 02/28/29

A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Phase: N/A Priority: Normal
NCT ID: NCT04928846 Org: User:
Start: 03/25/22 End: 03/31/28 Due: 03/31/29

A Study to Assess the Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), or Chronic Lymphocytic Leukemia (CLL)

Phase: N/A Priority: Normal
NCT ID: NCT05512390 Org: User:
Start: 04/26/23 End: 02/28/27 Due: 02/28/28

Progress at Work - The Impact of Adalimumab on Work Related Productivity in Patients With Rheumatoid Arthritis

Phase: N/A Priority: Normal
NCT ID: NCT02362074 Org: User:
Start: 01/21/15 End: 03/06/20 Due: 03/06/21

Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - An Observational Study in Germany (LIFE-C)

Phase: N/A Priority: Normal
NCT ID: NCT02615145 Org: User:
Start: 12/03/15 End: 03/26/18 Due: 03/26/19

Study to Evaluate the Relative Bioavailability of Two Risankizumab Drug Product Presentations in Healthy Volunteers.

Phase: N/A Priority: Normal
NCT ID: NCT05567029 Org: User:
Start: 09/28/22 End: 04/20/23 Due: 04/20/24

A Study to Evaluate the Effect of Intravenous (IV) Infusions of Risankizumab on Pharmacokinetics of Cytochome P450 Substrates in Adult Participants With Moderately to Severely Active Ulcerative Colitis or Crohn's Disease

Phase: N/A Priority: Normal
NCT ID: NCT04254783 Org: User:
Start: 05/27/20 End: 10/14/22 Due: 10/14/23

A Long-Term Study of Rovalpituzumab Tesirine

Phase: N/A Priority: Normal
NCT ID: NCT03543358 Org: User:
Start: 09/10/18 End: 11/26/19 Due: 11/26/20

A Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of Glecaprevir/Pibrentasvir in Pediatric Subjects With Genotypes 1-6 Chronic Hepatitis C Virus (HCV) Infection

Phase: N/A Priority: Normal
NCT ID: NCT03067129 Org: User:
Start: 03/20/17 End: 09/12/22 Due: 09/12/23

Real-World Study of Foslevodopa/Foscarbidopa to Assess Quality of Life Outcomes in Adult Participants With Advanced Parkinson Disease

Phase: N/A Priority: Normal
NCT ID: NCT06965374 Org: User:
Start: 06/04/25 End: 06/30/27 Due: 06/30/28

A Study to Assess Change in Disease Activity and Adverse Events (AEs) With Cariprazine in the Treatment of Depressive Episodes in Pediatric Participants Participants (10 to 17 Years of Age) With Bipolar I Disorder.

Phase: N/A Priority: Normal
NCT ID: NCT04777357 Org: User:
Start: 04/28/21 End: 03/31/27 Due: 03/31/28

Study to Assess the Adverse Events, Tolerability, and How Oral Doses of ABBV-932 Moves Through the Body in Healthy Adult Chinese Participants

Phase: N/A Priority: Normal
NCT ID: NCT07024797 Org: User:
Start: 08/18/25 End: 03/31/26 Due: 03/31/27

Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Lemzoparlimab With or Without Oral/IV Dexamethasone and in Combination With Oral/IV/Subcutaneous Anti-Myeloma Regimens in Adult Participants With Multiple Myeloma

Phase: N/A Priority: Normal
NCT ID: NCT04895410 Org: User:
Start: 01/17/22 End: 06/24/22 Due: 06/24/23

Study to Assess Adverse Events and Compare How Oral Ubrogepant and Oral Atogepant Moves Through the Body of Healthy Female Adult Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT05892757 Org: User:
Start: 07/11/23 End: 02/22/24 Due: 02/22/25

Real-World Study to Assess Subcutaneous Epcoritamab in Adult Participants With Diffuse Large B-Cell and Follicular Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT06830759 Org: User:
Start: 03/28/25 End: 09/30/31 Due: 09/30/32

Study of Oral Glecaprevir/Pibrentasvir Tablets in Participants Aged 12 Years or Older With Chronic Hepatitis C to Assess Sustained Virological Response

Phase: N/A Priority: Normal
NCT ID: NCT04577482 Org: User:
Start: 10/07/20 End: 09/03/22 Due: 09/03/23

A Study To Assess the Safety of OnabotulinumtoxinA (BOTOX) Intramuscular Injection in Adult Participants With Platysma Prominence

Phase: N/A Priority: Normal
NCT ID: NCT05134649 Org: User:
Start: 11/16/21 End: 08/18/23 Due: 08/18/24

A Study to Evaluate the Efficacy and Safety of Three Experimental Drugs Compared With Telaprevir (a Licensed Product) for Treatment of Chronic Hepatitis C Infection in Treatment-experienced Adults

Phase: N/A Priority: Normal
NCT ID: NCT01854528 Org: User:
Start: 06/30/13 End: 07/31/15 Due: 07/31/16

A Study of the Safety and Efficacy of Risankizumab in Adult Participants With Plaque Psoriasis Who Have Had a Suboptimal Response to Secukinumab or Ixekizumab

Phase: N/A Priority: Normal
NCT ID: NCT04102007 Org: User:
Start: 11/12/19 End: 11/07/22 Due: 11/07/23